FDA Determines Regulatory Review Period for SKYCLARYS Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for SKYCLARYS, a human drug product, following the submission of patent extension applications to the US Patent and Trademark Office (USPTO).